Phase Ii Neoadjuvant Clinical Trial Of Carboplatin And Eribulin In Women With Triple Negative Early Stage Breast Cancer (Nct01372579)

1017 Background: Platinum-based chemotherapy has been reported to have efficacy in patients with Triple Negative Breast Cancer (TNBC). Germline BRCA1/2 mutation status has been shown to be predictive of platinum response in patients with metastatic TNBC. In the neoadjuvant setting some, but not all patients with sporadic TNBC also achieve a pathologic complete response (pCR). This study evaluated the efficacy and toxicity of neoadjuvant treatment with carboplatin and eribulin in patients with early stage TNBC, and assessed the role of a HRD (homologous recombination deficiency) test to predict response. Methods: Patients with histologically confirmed early stage TNBC received carboplatin AUC 6 iv every 21 days and eribulin 1.4 mg/m2 day1 and day 8 every 21 days for four cycles. The primary endpoint of the study was pCR, with secondary endpoints including clinical response rate and safety of the combination. Tumor specimens were evaluated for BRCA1/BRCA2 mutations, BRCA1 promoter methylation, and HRD statu...